Purified Poloxamer 188 for Sickle Cell Vaso-Occlusive Crisis

Annals of Pharmacotherapy

Volumn 38, Issue 2, 2004, Pages 320-324

  Gibbs, Winter J ^b,c   Hagemann, Tracy M ^a  

^a PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c Department of Pharmacy ^*  (United States)

Author keywords

CRL 5861; Flocor; Purified poloxamer 188; Sickle cell vaso occlusive crisis

Indexed keywords

CRL 5861; FLOCOR; HYDROXYUREA; POLOXAMER;

BLOOD FLOW; BLOOD VESSEL WALL; BLOOD VISCOSITY; CELL DAMAGE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE; ERYTHROCYTE AGGREGATION; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MICROVASCULARIZATION; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANIMALS; CHILD; CLINICAL TRIALS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; POLOXAMER; SURFACE-ACTIVE AGENTS; TISSUE DISTRIBUTION;

EID: 1642458264     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D223     Document Type: Review

References (19)

1. Facts about sickle cell anemia. NIH publication 96-4057. www.nblbi. nih.gov/healtl/public/blood/sickle/sca_fact.txt (accessed 2003 Jul 27).
2. Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (Hb S) allele and sickle cell disease: a HuGE review. Am J Epidemiol 2000;151:839-45.
3. Embury SH, Hebbel RP, Mohandas N, Steinberg MG, eds. Sickle cell disease: basic principles and clinical practice. New York: Raven Press, 1994.
4. Yale SH, Nagib N, Guthrie T. Approach to the vaso-occlusive crisis in adults with sickle cell disease. Am Fam Physician 2000;61:1349-56.
5. Ballas SK. Sickle cell anemia: progress in pathogenesis and treatment. Drugs 2002;62:1143-72.
6. Orringer EP, Casella JF, Ataga KI, Koshy M, Adams-Graves P, Luchtman-Jones L, et al. Purified poloxamer 188 for treatment of acute vasoocclusive crisis of sickle cell disease: a randomized controlled trial. JAMA 2001;286:2099-106.
7. CRL-5861 (Flocor, purified poloxamer 188, RheothRx). Investigational therapeutic products. Bioscorpio Lifescience. www.bioscorpio.com (accessed 2003 Mar 21).
8. Emanuele RM. Flocor: a new anti-adhesive, rheologic agent. Exp Opin Invest Drugs 1998;7:1193-200.
9. Flocor technical brochure. CytRx Corporation. www.cytrx.com (accessed 2003 May 15).
10. Poloxamer 188. Drugdex drug evaluations [monograph online]. Luer J, Fukumoto M, Drugdex editorial staff. Volume 119, expires 3/2004. Greenwood Village, CO: Micromedex (accessed 2003 Dec 15).
11. Grindel JM, Jaworski T, Emanuele RM, Culbreth P. Pharmacokinetics of a novel surface-active agent, purified poloxamer 188, in rat, rabbit, dog and man. Biopharm Drug Dispos 2002;23:87-103.
12. Jewel RC, Khor SP, Kisor DF, LaCroix KAK, Wargin WA. Pharmacokinetics of RheothRx injection in healthy male volunteers. J Pharm Sci 1997;86:808-12.
13. Grindel JM, Jaworski T, Piraner O, Emanuele RM, Balasubramanian M. Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans. J Pharm Sci 2002;91:1936-47.
14. Adams-Graves P, Kedar A, Koshy M, Steinberg M, Veith R, Ward D. RheothRx (Poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood 1997;90:2041-6.
15. Collaborative Organization for RheothRx Evaluation (CORE). Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Circulation 1997;96:192-200.
16. Yusuf S and the Collaborative Organization for RheothRx Evaluation Trialists. Evaluation of RheothRx, a novel hemorheologic agent in acute myocardial infarction (abstract). Circulation 1995;92:1-24.
17. Schaer GL, Spaccavento LJ, Browne KF, Krueger KA, Krichbaum D, Phelan JM, et al. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction: results of a randomized, double-blind, placebo-controlled trial. Circulation 1996;94:298-307.
18. Flocor overview. CytRx Corporation. www.cytrx.com (accessed 2003 Dec 15).
19. Files BA, Ballas SK, Benjamin LJ, Wojtowicz-Praga S, Grindel JM. Multicenter trial of Flocor in patients with sickle cell disease and acute chest syndrome (abstract). Blood 1998;92:30b.